This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Tetrachlorodecaoxide
- DrugBank Accession Number
- DB05389
- Background
WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the body digests foreign, potentially harmful substances. The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer. The trial is being conducted in Germany at the University of Heidelberg and the National Centre for Tumor Diseases.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Synonyms
- TCDO
- Tetrachlorodecaoxygen
- External IDs
- WF 10
- WF10
Pharmacology
- Indication
Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, cancer/tumors (unspecified), HIV infection, and inflammatory disorders (unspecified).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Burns ••• ••• •••••••• Treatment of Decubitus ulcer ••• ••• •••••••• Treatment of Diabetic wound ••• ••• •••••••• Treatment of Hot water burns (scalds) ••• ••• •••••••• Treatment of Infected wound ••• ••• •••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
WF 10 is a 1: 10 dilution of tetrachlorodecaoxide (TCDO) formulated for intravenous injection. It was developed by Oxo Chemie in Switzerland as an adjunctive therapy to combination antiretroviral and opportunistic infection prophylaxis regimens in AIDS patients. WF 10 specifically targets macrophages. WF10 potentially modulates disease-related up-regulation of immune responses both in vitro and in vivo. Thus immune response is influenced in a way that inappropriate inflammatory reactions are downregulated.
Target Actions Organism UMacrophage erythroblast attacher Not Available Humans UScavenger receptor cysteine-rich type 1 protein M130 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image OXOFERIN Solution 6.9 Munit/5ml Topical บริษัท นีโอ ฟาร์ม จำกัด 2005-09-03 Not applicable Thailand 
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as non-metal chlorites. These are inorganic non-metallic compounds containing a chlorite as its largest oxoanion.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous non-metal compounds
- Class
- Non-metal oxoanionic compounds
- Sub Class
- Non-metal chlorites
- Direct Parent
- Non-metal chlorites
- Alternative Parents
- Inorganic oxides
- Substituents
- Inorganic oxide / Non-metal chlorite
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 549BT7IE1Q
- CAS number
- 92047-76-2
References
- General References
- Veerasarn V, Khorprasert C, Lorvidhaya V, Sangruchi S, Tantivatana T, Narkwong L, Kongthanarat Y, Chitapanarux I, Tesavibul C, Panichevaluk A, Puribhat S, Sangkittipaiboon S, Sookpreedee L, Lertsanguansinchai P, Phromratanapongse P, Rungpoka P, Trithratipvikul S, Lojanapiwat B, Ruangdilokrat S, Ngampanprasert P: Reduced recurrence of late hemorrhagic radiation cystitis by WF10 therapy in cervical cancer patients: a multicenter, randomized, two-arm, open-label trial. Radiother Oncol. 2004 Nov;73(2):179-85. [Article]
- External Links
- PubChem Compound
- 3000391
- PubChem Substance
- 175426992
- ChemSpider
- 2272021
- ChEMBL
- CHEMBL3707387
- Wikipedia
- WF10
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Human Immunodeficiency Virus (HIV) Infections 1 1 Completed Treatment Human Immunodeficiency Virus (HIV) Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Topical 6.9 Munit/1ml Solution Topical Solution Topical 6.9 Munit/5ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 502.0 mg/mL ALOGPS logP -0.91 ALOGPS logP 0.18 Chemaxon logS 0.77 ALOGPS pKa (Strongest Acidic) -4.6 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 40.13 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 9.02 m3·mol-1 Chemaxon Polarizability 3.91 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.5575 Blood Brain Barrier + 0.9535 Caco-2 permeable - 0.5923 P-glycoprotein substrate Non-substrate 0.8887 P-glycoprotein inhibitor I Non-inhibitor 0.985 P-glycoprotein inhibitor II Non-inhibitor 0.9956 Renal organic cation transporter Non-inhibitor 0.9579 CYP450 2C9 substrate Non-substrate 0.7831 CYP450 2D6 substrate Non-substrate 0.8516 CYP450 3A4 substrate Non-substrate 0.7326 CYP450 1A2 substrate Non-inhibitor 0.7958 CYP450 2C9 inhibitor Non-inhibitor 0.8319 CYP450 2D6 inhibitor Non-inhibitor 0.8739 CYP450 2C19 inhibitor Non-inhibitor 0.8037 CYP450 3A4 inhibitor Non-inhibitor 0.9522 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9887 Ames test Non AMES toxic 0.7006 Carcinogenicity Carcinogens 0.7081 Biodegradation Ready biodegradable 0.9707 Rat acute toxicity 2.3620 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9062 hERG inhibition (predictor II) Non-inhibitor 0.9725
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 119.27098 predictedDeepCCS 1.0 (2019) [M+H]+ 122.62375 predictedDeepCCS 1.0 (2019) [M+Na]+ 131.00032 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Actin binding
- Specific Function
- Plays a role in erythroblast enucleation and in the development of the mature macrophages. Mediates the attachment of erythroid cell to mature macrophages, in correlation with the presence of MAEA ...
- Gene Name
- MAEA
- Uniprot ID
- Q7L5Y9
- Uniprot Name
- Macrophage erythroblast attacher
- Molecular Weight
- 45286.895 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Scavenger receptor activity
- Specific Function
- Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damag...
- Gene Name
- CD163
- Uniprot ID
- Q86VB7
- Uniprot Name
- Scavenger receptor cysteine-rich type 1 protein M130
- Molecular Weight
- 125449.765 Da
Drug created at November 18, 2007 18:24 / Updated at June 12, 2020 16:52